Skip to main content
Best News Website or Mobile Service
 
WAN-IFRA Digital Media Awards Worldwide
Best News Website or Mobile Service
 
Digital Media Awards Worldwide
Hamburger Menu

Advertisement

Advertisement

World

Novavax 2022 COVID-19 vaccine deliveries off to slow start, shares drop

Novavax 2022 COVID-19 vaccine deliveries off to slow start, shares drop

A vial and sryinge are seen in front of a displayed Novavax logo in this illustration taken Jan 11, 2021. (File photo: REUTERS/Dado Ruvic/Illustration)

Novavax on Monday (May 9) revealed a sharp drop in first-quarter COVID-19 research funding and said it shipped less than a fourth of the total vaccine deliveries slated for 2022, dragging shares of the company down nearly 16 per cent after hours.

It sold 31 million doses of the vaccine in the quarter, a small fraction of the 2 billion shots it plans to send around the world in 2022.

Still, Novavax reiterated its forecast for total revenue of US$4 billion to US$5 billion for 2022, saying it expects shipments to key markets and sales to increase in the second quarter.

"We expect to see additional pull through within these markets in the coming months as demand continues with recent surges of COVID-19 around the world," chief commercial officer John Trizzino said.

The comments were in contrast to several other drugmakers that have started to pencil in a slowdown in demand for COVID-19 products due to a global vaccine supply glut and a likely decline in cases.

Novavax's grant revenue, from the US government and the Coalition for Epidemic Preparedness Innovations, dropped nearly 78 per cent to US$99 million.

Sales of its vaccine, NVX-CoV2373, brought in US$586 million in the quarter ended Mar 31, while the company earned US$19 million through royalties and adjuvant sales to its licensing partners including Serum Institute of India.

Novavax's recombinant protein vaccine, based on a more conventional technology, was expected to persuade some sceptics of the mRNA technology used by companies like Pfizer and Moderna. However, it has been plagued by manufacturing and regulatory delays as well as a slow uptake in key markets like the EU.

The company said on Monday it plans to initiate a late-stage study to test its vaccine in children aged 5 to 11 years by the third quarter.

BOOKMARK THIS: Our comprehensive coverage of the COVID-19 pandemic and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus pandemic: https://cna.asia/telegram

Source: Reuters/fh
Categories

Advertisement

Also worth reading

Advertisement